US 9173957
FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC
granted A61KA61K45/06A61P
Quick answer
US patent 9173957 (FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC) held by Five Prime Therapeutics, Inc. expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K45/06, A61P, A61P1/02, A61P1/04